York Health Economics Consortium

💡 Presentations Announcement: ISPOR EU 2026 The YHEC team is getting everything ready for an exciting conference, and we are delighted to announce that we will be hosting a panel on environmental sustainability in HTA. 🗓️ Panel: Integrating Environmental Sustainability into HTA: Global Policy Archetypes and Future Directions for Access Decision-Making 📍 When & Where: Monday 09 November, 16.45 - 17.45 🗣️ Speakers: Stuart Mealing, Director of Pharmaceutical Consulting at YHEC Beyond our panel, we are also excited to share that YHEC has 18 posters throughout the conference, highlighting our latest work and insights across literature reviews and evidence synthesis, economic evaluation, expert elicitation and methods research. If you are attending ISPOR, make sure to add our panel and poster presentations to your schedule. We’d love to see you there and take your questions during the session. You can also find us at Booth 719! 👉 Check out our full conference schedule here: https://lnkd.in/eBatigKN #ISPOR #HealthEconomics #HEOR #Pharma

💡 Working Group: World Orphan Drug Congress Europe 2026 We are thrilled to share that YHEC will be leading an interactive working group at this year's event! Stuart Mealing, Andria Joseph and Charlotte Ahmadu will be hosting a roundtable discussion on defining minimum evidence standards for demographic diversity in rare diseases. The working group discussion is titled: Who Makes the Cut? Defining a Minimum Evidence Standard for Demographic Diversity Don’t miss this opportunity to contribute your perspective to this exploratory discussion as we bring together patients, regulators, HTA bodies, clinicians, researchers, and industry to examine what demographic and equity-relevant information is minimally necessary to judge if rare disease evidence is sufficiently representative and meaningful. 📅 When: Tuesday 27 October 🕒 Time: 11:30 AM to 12:30 PM #WODC #WorldOrphanDrugCongress #RareDisease #OrphanDrugs #MarketAccess #PatientAdvocacy

💡 Working Group: World Orphan Drug Congress Europe 2026 We are thrilled to share that YHEC will be leading an interactive working group at this year's event! Stuart Mealing, Andria Joseph and Charlotte Ahmadu will be hosting a roundtable discussion on defining minimum evidence standards for demographic diversity in rare diseases. The working group discussion is titled: Who Makes the Cut? Defining a Minimum Evidence Standard for Demographic Diversity Don’t miss this opportunity to contribute your perspective to this exploratory discussion as we bring together patients, regulators, HTA bodies, clinicians, researchers, and industry to examine what demographic and equity-relevant information is minimally necessary to judge if rare disease evidence is sufficiently representative and meaningful. 📅 When: Tuesday 27 October 🕒 Time: 11:30 AM to 12:30 PM #WODC #WorldOrphanDrugCongress #RareDisease #OrphanDrugs #MarketAccess #PatientAdvocacy

Attending HTAi 2026? Don’t miss our panel on the growing role of environmental sustainability in assessing digital health technologies. Bringing together global perspectives, the session will examine emerging methods and policy approaches, challenges in resource-limited settings, and patient/clinician perspectives on balancing sustainability, innovation and equitable decision-making. Through discussion and an interactive case study, the panellists will highlight how HTA can help to embed environmental sustainability within decision-making and support more resilient and equitable health systems. 📅 When: Wednesday 10 June 🕒 Time: 10:00 to 11:00 #HTAi2026Istanbul #ESHTA #HTA #YHEC

Health equity is moving to the centre of HTA and methods need to keep pace. In our latest blog, YHEC’s Hayden Holmes, Angel Varghese and Robert Malcolm discuss how distributional cost-effectiveness analysis (DCEA) is helping decision makers assess not just overall health gains, but how those gains are distributed. They explore: • What health equity means in economic evaluation • How DCEA quantifies trade-offs between efficiency and fairness • Growing international momentum (including NICE and global guidelines) • Key challenges around data, consistency, and implementation As expectations on HTA evolve, incorporating equity considerations is becoming increasingly important for robust, policy-relevant analysis. 👉 Read the full discussion: https://lnkd.in/e_hydATe. #HealthEconomics #HTA #HealthEquity #DCEA #EvidenceBasedMedicine

Can we evaluate digital health interventions more effectively by looking beyond the traditional randomised controlled trial? In his upcoming panel at the World Evidence, Pricing and Access (WEPA) Congress 2026, YHEC’s Robert Malcolm will be discussing: "Leveraging the European Health Data Space to advance reimbursement for digital behaviour change interventions." While randomised controlled trials remain the gold standard for reducing bias, they can struggle to capture the nuances of long-term adherence and real-world usage of digital behaviour change interventions. By leveraging centralised, real-world data across the EU, we have the opportunity to support more efficient reimbursement pathways by enhancing our understanding of how digital interventions perform in everyday settings and streamlining evaluation processes by pooling effectiveness data. We look forward to a nuanced discussion on how we can use better data integration to bring effective digital tools to patients more efficiently. #DigitalHealth #RealWorldData #WorldEPACongress #MarketAccess #HTA